Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
复制标题
药物性肝损伤：亚太肝脏研究协会共识指南
DOI：
10.1007/s12072-021-10144-3
复制
发表时间：
2021-02-27
影响因子：
6.6
通讯作者：
Sarin, Shiv K.
中科院分区：
文献类型：
--
作者：
Devarbhavi, Harshad;Aithal, Guruprasad;Sarin, Shiv K.
特殊的药物所致的肝损伤类似于急性和慢性肝病。由于缺乏病原学诊断血清学标志物，它被忽视和认识不足。其后果可能各不相同，从无症状到自限性疾病，再到导致急性肝功能衰竭的严重肝损伤。它的发病率在亚洲可能比世界其他地区更常见，主要是因为在亚洲国家治疗结核病和普遍使用传统药物和免费药物造成的肝脏毒性。APASL关于帝力的协商一致准则简明扼要地介绍了各个方面，包括关于帝力的现有循证信息，特别强调由于亚洲使用抗结核药物以及传统和补充药物而导致的帝力。
Idiosyncratic drug-induced liver injury mimics acute and chronic liver disease. It is under recognized and underrecognised because of the lack of pathognomonic diagnostic serological markers. Its consequences may vary from being asymptomatic to self-limiting illness to severe liver injury leading to acute liver failure. Its incidence is likely to be more common in Asia than other parts of the world, mainly because of hepatotoxicity resulting from the treatment of tuberculosis disease and the ubiquitous use of traditional and complimentary medicines in Asian countries. This APASL consensus guidelines on DILI is a concise account of the various aspects including current evidence-based information on DILI with special emphasis on DILI due to antituberculosis agents and traditional and complementary medicine use in Asia.